Online supplement to: Descriptive Comparisons of the Effect of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: The Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results. *The Journal of Rheumatology*. doi:10.3899/jrheum.191209


ONLINE SUPPLEMENTARY DATA

Supplementary Figure 1. Study flow chart: Patient disposition for apremilast, methotrexate, and bDMARD initiators with oligoarticular psoriatic arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. bDMARD: biologic disease-modifying anti-rheumatic drug.

150 had a relevant 6month follow-up visit (apremilast: n=34; 329 initiated apremilast, methotrexate: n=15; methotrexate, or bDMARD bDMARD: n=101) monotherapy as the first initiation during follow-up with 179 did not have a oligoarthritis relevant follow-up visit 1593 had oligoarthritis within the specified 1717 PsA patients during follow-up 1264 initiated another form of timeframe enrolled with 1+ visit therapy as the first initiation between June 1, 2014, during follow-up with 124 did not have and March 1, 2018 oligoarthritis or did not initiate a oligoarthritis during relevant drug therapy during follow-up follow-up

Online supplement to: Descriptive Comparisons of the Effect of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: The Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results. *The Journal of Rheumatology*. doi:10.3899/jrheum.191209

Supplementary Figure 2. Achievement of HAQ-DI MCID: Proportion of patients with HAQ-DI score available at baseline achieving ≥0.35-point improvement in the Health Assessment Questionnaire-Disability Index minimum clinically important differences at 6 months. bDMARD: biologic disease-modifying anti-rheumatic drug. n/N: number of responders/number of patients with sufficient data for evaluation.



Online supplement to: Descriptive Comparisons of the Effect of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: The Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results. *The Journal of Rheumatology*. doi:10.3899/jrheum.191209

Supplementary Figure 3. Nail disease complete responders: Proportion of patients with presence of physician-reported clinical characteristics of nail psoriasis at baseline who were without physician-reported clinical characteristics of nail psoriasis at 6 months. bDMARD: biologic disease-modifying anti-rheumatic drug. n/N=number of responders/number of patients with sufficient data for evaluation.

